

1	A combined small molecule and loss-of-function screen uncovers estrogen
2	receptor alpha and CAD as host factors for HDV infection and antiviral targets
3	
4	
5	Eloi R. Verrier <sup>1,*</sup> , Amélie Weiss <sup>2</sup> , Charlotte Bach <sup>1</sup> , Laura Heydmann <sup>1</sup> , Vincent Turon-Lagot <sup>1</sup>
6	Arnaud Kopp <sup>2</sup> , Hussein El Saghire <sup>1</sup> , Emilie Crouchet <sup>1</sup> , Patrick Pessaux <sup>1,5</sup> , Thomas Garcia <sup>3</sup> ,
7	Patrick Pale <sup>3</sup> , Mirjam B. Zeisel <sup>1</sup> , Camille Sureau <sup>4</sup> , Catherine Schuster <sup>1</sup> , Laurent Brino <sup>2</sup> ,
8	Thomas F. Baumert <sup>1,5,6,*</sup>
9	
10	<sup>1</sup> Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et
11	Hépatiques UMRS_1110, F-67000 Strasbourg, France ; <sup>2</sup> IGBMC, Plateforme de Criblage
12	Haut-débit, UMR7104 CNRS U1258 Inserm, Illkirch, France; <sup>3</sup> Laboratoire de Synthèse,
13	Réactivité Organiques et Catalyse, Institut de Chimie, UMR 7177 CNRS, Université de
14	Strasbourg, Strasbourg, France ; <sup>4</sup> INTS, Laboratoire de Virologie Moléculaire, Paris, France;
15	<sup>5</sup> Institut Hospitalo-universitaire, Pôle Hépato-digestif, Nouvel Hôpital Civil, Strasbourg,
16	France, <sup>6</sup> Institut Universitaire de France, Paris, France
17	
18	
19	*Corresponding authors: Prof. Thomas F. Baumert, MD and Dr. Eloi Verrier, PhD; Inserm
20	UMR_S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 3 rue Koeberlé,
21	67000 Strasbourg, France; Phone: +33 3 68 85 37 03, Fax: +33 3 68 85 37 24, e-mails:
22	thomas.baumert@unistra.fr and e.verrier@unistra.fr.
23	

### 24 ABSTRACT

25 **Objective:** Hepatitis D virus (HDV) is a circular RNA virus co-infecting hepatocytes with 26 hepatitis B virus. Chronic hepatitis D results in severe liver disease and an increased risk of 27 liver cancer. Efficient therapeutic approaches against HDV are absent.

28 **Design:** Here, we combined an RNAi loss-of-function and small molecule screen to uncover

- 29 host-dependency factors for HDV infection.
- 30 **Results:** Functional screening unraveled the HIF-signaling and insulin resistance pathways,

31 RNA polymerase II, glycosaminoglycan biosynthesis and the pyrimidine metabolism as virus-

hepatocyte dependency networks. Validation studies in primary human hepatocytes identified the CAD enzyme and estrogen receptor 1 (ESR1) as key host factors for HDV life cycle. Mechanistic studies revealed that the two host factors are required for viral replication. Inhibition studies using PALA and Fulvestrant, specific CAD and ESR1 inhibitors respectively, uncovered their impact as antiviral targets.

- 37 Conclusion: The discovery of HDV host-dependency factors elucidates the pathogenesis of
   38 viral disease biology and opens therapeutic strategies for HDV cure.
- 39

40 **KEYWORDS:** Antiviral therapy; Hepatitis D; Screening; Liver

41

- 42 Word count: 3989; References: 50
- 43

Abbreviations: HDV: hepatitis D virus; HBV: hepatitis B virus; HSPG: heparan sulfate
proteoglycan; NTCP: sodium taurocholate co-transporting polypeptide; HD-Ag: delta antigen;
RNP: ribonucleoprotein; EBV: Epstein-Barr virus; CAD: carbamoyl-phosphate synthetase 2,
aspartate transcarbamylase, and dihydroorotase; ESR1: estrogen receptor 1; PHH: primary
human hepatocytes; DHODH: dihydroorotate dehydrogenase; PALA: N-(Phosphonoacetyl)L-aspartic acid; TFV: tenofovir;

50

53	What is already known about this subject?
55	What is already known about this subject?
54	Chronic hepatitis D is the most severe form of viral hepatitis
55	Efficient therapeutic strategies are absent
56	Hepatitis D virus is a small HBV satellite virus
57	Knowledge about HDV-hepatocyte interactions is limited
58	HDV host-dependency factors are largely unknown
59	What are the new findings?
60	A RNAi screen identified ESR1 and CAD as novel host factors for HDV infection
61	The inhibition of CAD restricts HDV infection through uridine depletion
62	ESR1 and CAD are functionally linked by transcriptional activation of gene expression
63	• ESR1 and CAD inhibitors Fulvestrant and PALA, respectively, specifically inhibit HDV
64	replication in a dose-dependent manner in human hepatocytes
65	CAD and ESR1 are previously undiscovered targets for antiviral therapies
66	
67	Significance of the study
68	How might it impact on clinical practice in the foreseeable future?
69	• The discovery of HDV host-dependency factors opens the door for novel therapeutic
70	strategies against chronic hepatitis D – a major unmet medical need
71	• Fulvestrant and PALA-like molecules are candidate compounds for HDV antivirals to
72	enter preclinical development
73	
74	
75	
76	
77	
78	

SUMMARY BOX

### 79 INTRODUCTION

80 Hepatitis delta virus (HDV) infects human hepatocytes and causes acute acerbation of liver 81 disease in patients chronically infected with hepatitis B virus (HBV)[1]. Among HBV infected 82 patients, 5 to 10% are co-infected with HDV[2]. HDV co- or sur-infection in HBV carriers 83 induces more severe disease compared to infection with HBV alone. This includes a greater 84 likelihood of experiencing liver failure and a more rapid progression to liver cirrhosis, with a 85 markedly increased risk of developing hepatocellular carcinoma[3]. Consequently, chronic 86 hepatitis D is considered as one of the most severe forms of viral hepatitis. Treatment with 87 HBV nucleos(t)ide analogues is not effective at reducing HDV replication or disease. Moreover, the virus is only poorly controlled by the current IFN-based therapies[3] and to 88 89 date, no treatment allows efficient cure of hepatitis D with eradication of the virus and its 90 associated disease[4-6]. Thus, there is a major unmet medical need for curative therapies.

HDV is a small, circular RNA HBV satellite virus related to plant viroids using HBV 91 envelope proteins to assemble its infectious particles [1, 5, 6]. Consequently, it can only be 92 93 propagated by HBV-infected hepatocytes producing HBV envelope proteins (HBsAg). The 94 HDV genome is a circular 1.7 kb single-stranded negative-sense RNA molecule (for a review 95 on HDV virology and pathogenesis, see [5]). The HDV life cycle starts with virus entry into 96 hepatocyte after attachment to heparan sulfate proteoglycans (HSPG) at the cell surface[5, 97 7]. As HBV and HDV share the same envelope proteins, they appear to share the same entry 98 pathway and receptor(s), including the sodium taurocholate co-transporting polypeptide 99 (NTCP) and Glypican 5 (reviewed in [5, 6, 8]). The HDV genome is then imported in the 100 nucleus, and three types of RNAs are transcribed by the host RNA polymerase II: replication 101 is initiated by synthesis of an anti-genomic RNA that serves as a template for the production 102 of new HDV genomic RNA, and HDV mRNA from genomic RNA[5]. mRNA transcripts 103 contain one unique open reading frame encoding the delta antigen (HDAg) which exists in 104 two forms (small version S-HDAg and large version L-HDAg) which play differential roles in 105 the HDV life cycle[5, 6]. Indeed, S-HDAg is essential to HDV replication, while prenylation of 106 L-HDAg leads to the inhibition of HDV replication and is crucial for binding to HBV envelope

107 proteins and virion assembly[6]. In the nucleus, L-HDAgs bind to the *de novo* HDV genomic 108 RNA to form a new ribonucleoprotein (RNPs), which is exported to the cytoplasm and 109 interacts with HBsAgs at the endoplasmic reticulum to form new infectious virions, which are 110 then secreted to propagate further rounds of HDV infection[6]. While the molecular virology 111 of HDV has been elucidated, the role of host-dependency factors for HDV infection remains 112 largely unknown[5].

113 A unique feature of HDV is the apparent lack of non-structural protein encoded by the 114 viral genome (including viral polymerase), making it highly dependent of the host machinery 115 for its replication. Targeting host factors is an emerging concept in the treatment of infectious 116 diseases including hepatitis viruses[9-12]. Two host compounds targeting HDV factors have 117 been developed up to clinical proof-of-concept: These include Myrcludex B, a small peptide 118 targeting HBV/HDV entry factor NTCP and the prenylation inhibitor Lonafranib[4, 13, 14]. 119 Both compounds demonstrated a significant clinical antiviral effect in chronically infected 120 patients[4, 13, 14], supporting the validity of the concept of host-targeting antivirals for HDV 121 infection. However, data on long-term safety, potential resistance in subsets of patients and 122 sustained virological response remain to be determined. Thus, complementary approaches 123 targeting other host factors and/or steps of the HDV life cycle are needed for curative 124 therapies.

Taking advantage of our recently developed robust HDV infection system for the study of HDV-host factor interactions[7] combined with a dual screening approach, we aimed to uncover HDV host-dependency factors as antiviral targets.

128

# 129 **RESULTS**

A high-throughput RNAi loss-of-function screen uncovers hepatocyte hostdependency factors required for HDV infection. To identify host factors required for HDV infection, we performed a high-throughput loss-of-function screen using the HDV-susceptible cell line Huh-106[7]. Since one key goal was the discovery of druggable host targets, we used a library comprising siRNAs targeting 7567 genes which have been selected as targets

for therapeutics, including kinases, proteases, phosphatases, G protein–coupled receptor, ion channels, ubiquitin ligases, protein involved in senescence, autophagy, DNA repair, and targetable nuclear receptors. Huh-106 cells were transfected with siRNAs pools 48 hours before inoculation with HDV (Figure 1A) with an optical immunostaining-based viral protein (HDAg) readout 7 days after infection. The silencing of expression of HDV host factor NTCP was used as functional positive control (Figure 1B-C). The results of the primary screen are presented in Table S1.

Using the hit selection algorithm described in Methods and Figure 1E, we identified 143 191 host factor genes showing a robust correlation between gene silencing and level of HDV 144 infection, moderate toxicity of gene-specific siRNA and their expression in the liver (Figure 145 1D-E and Table S2). The threshold of hit selection (described in Figure 1E) was based on 146 the functional effect of *SLC10A1* silencing (approximately 45% decrease in HDV infection, 147 Table S1). The hit rate of 191 genes corresponds to 2.5% of total genes, which is similar to 148 screens for other virus host factor-dependency screens[15, 16].

149 Functional pathway analysis using KEGG pathways identified a network of host 150 factors belonging to HSPG biosynthesis, including EXT1 and EXT2 (Figure 2A-B). These 151 encode major exostosins, key HSPG-related enzymes genes two exhibiting 152 glycosyltransferase activities and involved in the elongation of HS chains[17]. Moreover, 153 several subunits of the RNA polymerase II were identified in our screen (Figure 2B), 154 including specific subunits such as POLR2G or POLR2I, encoding Rpb7 and Rpb9, which 155 play key roles in the initiation of transcription and binding to DNA template for an accurate 156 selection of the transcription start sites, respectively[18, 19]. The identification of HSPG 157 enzymes and RNA polymerase II as known HDV-related pathways[5, 7] validates our 158 approach for host factor discovery (Figure 2). Importantly, the screen identified several 159 previously unknown HDV-related networks, such as the hypoxia inducible factor 1 alpha 160 (HIF-1α) signaling pathway, known to enhance the replication of several RNA and DNA 161 viruses such as Epstein-Barr virus (EBV) and HIV[20, 21]. Interestingly, the HIF-1 $\alpha$  signaling 162 pathway also plays a key role in hepatocarcinogenesis and liver tumor progression[22, 23]

through its ability to target the expression of oncogenic genes such as the proliferationspecific transcription factor Forkhead box M1[24]. HIF-1α overexpression in HCC has been correlated with worse clinical outcomes and is considered as a poor prognosis factor and molecular target for liver disease therapy[24]. Interestingly, the highly significant scoring of insulin resistance-related pathways highlights the importance of hepatocyte metabolism as host-dependency factors on HDV infection (Figure 2).

169 Finally, we identified several host factors involved in the biosynthesis of pyrimidine,170 including *CANT1*, *ENTPD5*, and *CAD*.

171

172 The pyrimidine biosynthesis enzyme CAD is a key host factor for HDV infection and 173 antiviral target in human hepatocytes. Given its high impact on HDV infection, functional 174 relevance, liver expression and targetability, we focused on CAD, encoding the carbamoyl-175 phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), an enzyme 176 playing a key role in the pyrimidine biosynthesis (Table S2; Figure 2)[25]. Silencing of CAD 177 led to a robust decrease in HDV infection (Figure 3A). CAD is a trifunctional enzyme 178 catalyzing the first steps of pyrimidine biosynthesis[26]. Interestingly, CAD expression is 179 known to be regulated by activated estrogen receptor 1 (ESR1) which binds to the 180 transcription factor SP1[27], two other host-dependency factors uncovered by the RNAi 181 screen (Figure 3A). These data suggest a key role of the pyrimidine biosynthesis pathway 182 and its associated nuclear proteins for the HDV life cycle.

We next investigated the functional role of CAD in HDV infection. We first performed additional silencing studies using individual *CAD*-specific siRNA. As shown in Figure 3B-D, a strong reduction of HDV RNA were observed after transfection of Huh-106 cells with the 4 individual siRNAs composing the siRNA pool, validating the key role of CAD expression in HDV infection. Notably, *CAD* expression was not significantly affected by HDV infection (Figure 3E).

Aiming to characterize the potential of CAD as an antiviral target, we synthetized a specific inhibitor of CAD, sparfosic acid or PALA (N-(<u>Phosphonoacetyl</u>)-<u>L-aspartic acid)[26]</u>.

191 PALA is an aspartic acid derivative, which inhibits the aspartate carbamoyltransferase 192 activity of the enzyme. We then investigated the antiviral activity of PALA in HDV-infected 193 Huh-106 cells. As shown in Figure 3F, PALA dose dependently inhibits HDV infection with an 194  $IC_{50} = 1.2 \mu M$ . Notably, a decrease in cell viability was observed after 7 days of culture.

To validate this result in the most physiological model for HDV infection, we investigated the antiviral activity of PALA using HDV infection of primary human hepatocytes (PHH). Interestingly, while no toxicity was observed in PHH even at high doses (100  $\mu$ M), the IC<sub>50</sub> of PALA was slightly higher in PHH (Figure 3G), which may reflect differences in uridine pools and/or CAD expression in rapidly dividing Huh7-based cells versus non-dividing PHH in cell culture[28].

201 To investigate the mechanism of action of CAD-HDV interaction, we performed a 202 rescue experiment using PALA and uridine-supplemented medium. Northern blot detection of 203 HDV genomic RNA in infected cells revealed that the addition of uridine in PALA-treated cells 204 restored HDV infection, validating the functional relevance of pyrimidine pathway for HDV 205 replication (Figure 4A). Notably, PALA at a concentration of 2.5 µM induced a strong 206 decrease in HDV infection which was efficiently rescued by uridine treatment (Figure 4B-C). 207 This dose was then selected for further functional studies. Importantly, no direct interaction 208 was observed between CAD and the HDV antigens (Figure 4D). As the inhibition of 209 pyrimidine pathway has been shown to stimulate the innate antiviral response with 210 subsequent inhibition of viral propagation [29], we next assessed the expression of IFNB1 211 following PALA treatment in Huh-106 cells. As shown in Figure 4E, no IFNB1 induction was 212 observed after treatment with either PALA or Brequinar, targeting dihydroorotate 213 dehydrogenase (DHODH), suggesting an absence of innate immune stimulation by 214 pyrimidine inhibitors in hepatocyte-derived cells.

To further validate the involvement of the biological function of CAD in HDV infection, cell culture medium was then complemented using either glutamine (Glu, the initial substrate of CAD), or dihydroorotate (DHO, the final product of CAD) (Figure 5A, as described in[25]). As shown in Figure 5B and Figure S1, while glutamine treatment had no effect on

intracellular HDV RNA, DHO treatment in PALA-treated cells restored HDV RNA to non treated levels, suggesting that PALA antiviral activity is linked to CAD physiological function.

To map the replication steps targeted mediated by CAD and targeted by PALA, we performed Northern blot analyses of HDV RNA allowing to quantify the HDV genome and anti-genome in the presence or absence of PALA. As shown in Figure 5C, PALA treatment effectively decreased the levels of both HDV genomic and antigenomic RNAs. Moreover, this inhibition was already observed during the early stages of viral replication (Figure S2). These data demonstrate that PALA inhibits all the steps of HDV replication including the synthesis of antigenomic RNA (Figure 5C).

Next, we performed kinetic studies adding PALA pre-, peri- and HDV post-infection (Figure 5D). PALA potently inhibited HDV infection given at any time before, during and following initiation of replication. Interestingly, the inhibitory effect was most pronounced when PALA was added prior or during initiation of replication. Finally, to exclude effects on other steps of the early HDV life cycle, we studied the effect of PALA treatment on HDV binding to the Huh-106 cell surface. The absent effect on HDV binding further confirms HDV replication as the life cycle step targeted by PALA (Figure 5E).

235 To test the specificity of the pyrimidine pathway for HDV infection, we treated HBV-236 producing HepAD38 cells with PALA. As shown in Figure 5F, PALA did not modulate HBV 237 antigen production as shown by an absent effect on HBeAg and HBsAg secretion. While 238 tenofovir (TFV) treatment dose-dependently inhibited HBV replication, PALA had no effect on 239 HBV DNA in the supernatant of HepAD38 cells (Figure 5G). Finally, the silencing of CAD 240 expression did not affect HBV infection in HepG2-NTCP cells (Figure 5H). These results 241 suggest that the pyrimidine/CAD pathway is relevant for HDV but not HBV replication. 242 Collectively, our results identify CAD as a key HDV host factor involved in HDV replication 243 and target for antiviral therapy.

244

A small molecule screen uncovers ESR1 inhibitor Fulvestrant as host targeting agent.
Next, we performed a small molecule screen using the Prestwick library, containing 1284

FDA-approved drugs (Figure 6A). Among the molecules exhibiting an antiviral activity against HDV we identified Fluvastatin and Cyclosporine A, two well described NTCP inhibitors (Table S3), confirming the validity of the screen. Interestingly, Ribavirin, a broad antiviral nucleoside analog[30] previously used for the treatment of chronic hepatitis C[31] exhibits a marked antiviral activity against HDV (Table S3). In the same vein, Nelfinavir, a protease inhibitor presenting anti-retroviral activity[32] was also identified in the drug screen (Table S3).

253 Given our discovery of ESR1 as HDV host-dependency factor we next focused on 254 ESR1-targeting agents. The library includes several agonists and antagonists of ESR1, as 255 well as characterized targets for endocrine therapy in breast cancer[33]. Interestingly, the 256 ESR1 antagonist Fulvestrant exhibited a marked, significant and dose-dependent antiviral 257 effect against HDV, whereas Tamoxifen and Toremifen, two ESR1 modulators with 258 estrogenic effects in the liver[34] increased HDV infection, validating the importance of ESR1 259 in HDV infection (Figure 6B-C). Interestingly, a 48 h-treatment started after virus inoculation 260 induced a marked decrease in HDV-infected cells (Figure 5D), suggesting an effect on HDV 261 replication.

262 Next, we aimed investigate the mechanism of action of the antiviral activity of Fulvestrant by investigating a functional link of ESR1 and CAD suggested by protein/protein 263 264 interaction studies[27]. To address this question, CAD expression was analyzed in Huh-106 265 cells and PHH in the presence or absence of the ESR1-antagonist (Figure 6E-G). As shown 266 in Figure 6G, Fulvestrant treatment resulted in a loss of CAD expression in both Huh-106 cell 267 line and PHH, suggesting that the antiviral activity of ESR1-inhibitor Fulvestrant is mediated 268 by ESR1-mediated down-regulation of CAD expression, which in turn is required for HDV 269 replication, confirming the previous observations with PALA.

Taken together, our dual screening approach uncovers the pyrimidine pathway and its associated and regulatory proteins as host factors for HDV infection and targets for antiviral therapy.

273

274

### 275 **DISCUSSION**

Chronic hepatitis D is the most severe form of viral hepatitis and at present time no treatment 276 277 allows robust viral clearance. Using a dual screening approach we identified ESR1 and CAD 278 as host factors and antiviral targets for HDV infection. The functional impact of the pyrimidine 279 biosynthesis for HDV replication is corroborated by (i) a marked decrease in HDV infection 280 after CAD and ESR1 silencing; (ii) a significant antiviral effect of ESR1 and CAD inhibitors 281 PALA and Fulvestrant and (iii) kinetic experiments mapping viral replication as the step of the 282 viral life cycle mediated by these host factors and targeted by the antivirals (vi) validation 283 studies in primary human hepatocytes.

284 Whereas the molecular virology of HDV is well described, the molecular interactions 285 between the virus and liver host factors are still largely unknown[5]. In mammalian cells, the 286 pyrimidine biosynthesis pathway leads to the production of *de novo* nucleotides and plays a 287 key role in RNA and DNA production, as well as protein glycosylation or cell membrane 288 assembly[25]. Moreover, uridine nucleotides and derivatives regulate key physiological 289 processes, such as lipid metabolism, regulation of normal central nervous system activity or 290 modulation of reproduction[35], making this pathway a major actor of important metabolic 291 processes. As a source of nucleotides for HDV RNA, this pathway is likely to be required for 292 optimal virus replication. Moreover, as a key regulator of viral glycosylation[25], an alteration 293 of this pathway may alter posttranslational modification of host or viral proteins, disrupting 294 viral infection.

295 CAD is a multifunctional enzyme exhibiting carbamoylphosphate synthetase, 296 aspartate transcarbamoylase, and dihydroorotase activities catalyzing the three first steps of 297 the pyrimidine biosynthesis pathway[36], playing a key role in HDV infection as such. The 298 observed antiviral activity of the CAD-specific inhibitor PALA validates the importance of this 299 factor and pathway in HDV infection. It is of interest to note that another enzyme of the 300 pyrimidine biosynthesis pathway DHODH, which catalyzes the production of orotate from 301 DHO, has been described as an antiviral target by small molecule GSK983[37]. Here, we 302 confirmed that the CAD-mediated DHO and uridine starvation is responsible for the observed

303 antiviral effect (Figures 4 & 5). Interestingly, HSPG synthesis has been shown to be 304 dependent on the pyrimidine synthesis pathway in a CAD-defective animal model[38]. 305 However, we did not observe any effect of CAD inhibition on either HBV infection or HDV 306 entry (Figure 5 E-H). While recent studies have suggested that the inhibition of pyrimidine 307 biosynthesis can stimulate innate antiviral responses[29], no induction of IFN expression was 308 observed in our model (Figure 4E). Thus, it is likely that the modulation of CAD activity or 309 expression affects HDV infection through its classical enzymatic activity linked to pyrimidine 310 metabolism, mainly affecting viral replication through uridine starvation, affecting both 311 genomic and antigenomic HDV RNAs. In this context, our study suggests that the first steps 312 of replication are particularly susceptible to PALA. These results are consistent with the 313 timing of HDV RNA amplification, much more pronounced during the early phase of 314 replication, before L-HDAg-mediated slow-down of replication[5].

Among the genes regulating the pyrimidine pathway, we identified *ESR1* as a HDV host-dependency factor and antiviral target. ESR1 is a nuclear hormone receptor expressed in the mammary gland and female reproductive track, but also in lung and liver[39]. In our mechanistic analyses, we show that ESR1 inhibition by Fulvestrant led to a decrease in CAD protein expression which most likely explains the antiviral effect of the molecule.

320 Our screening strategy also identified small molecules exhibiting significant antiviral 321 activity against HDV infection. Among them was found ribavirin, a nucleoside analog 322 previously used for the treatment of chronic HCV infection[40]. Given its concentration in the 323 primary screen (10 µM), HDV inhibition is most likely due to the ability of ribavirin to inhibit de 324 novo synthesis of GTP as recently suggested as a possible mechanism for the inhibition of 325 hepatitis E virus (HEV) replication in Huh7 cells (IC<sub>50</sub> of 18.9 µM for GTP depletion; EC<sub>50</sub> of 3 326 µM for HEV replication[41]). However, clinical attempts to treat hepatitis D using ribavirin 327 were largely unsuccessful[4].

328 Collectively, we identified previously undiscovered pathways and host factors for HDV 329 infection and antiviral targets. Host targeting agents are a promising approach for the 330 development of new antiviral treatments, notably because they limit the emergence of 331 resistant variants[8-10, 42]. In particular for RNA viruses, which do not integrate into the 332 genome, host targeting agents hold promise for viral cure[43]. Indeed, in chronic HCV 333 infection antibodies targeting a viral host entry factor Claudin-1 cure viral infection in a state-334 of-the-art mouse model[12], and a miRNA-122 antagonist has been shown to cure chronic 335 HCV infection in monotherapy in a subset of patients[44]. Two host compounds targeting HDV factors have been developed up to clinical proof-of-concept: these include Myrcludex B, 336 337 a small peptide targeting HBV/HDV entry factor NTCP and the prenylation inhibitor 338 Lonafranib[4, 13, 14]. In randomized clinical trials, both compounds demonstrated a 339 significant and robust antiviral effect in chronically infected patients[4, 13, 14], supporting the 340 validity of the concept of host-targeting antivirals for HDV infection. However, long-term 341 safety, potential resistance in subsets of patients and data on sustained virological response 342 remain to be determined. The discovery of novel host factors described in this study may 343 overcome these limitations by complementary, safer and more efficient approaches. 344 Compounds targeting essential host factors of the viral replication step may be conceptually 345 superior to entry or prenylation inhibitors by targeting the most vulnerable step of the viral life 346 cycle. Indeed, viral replication is the target of many effective clinically licensed antiviral 347 therapies such as nucleoside analogues for HBV infection or polymerase/protease inhibitors 348 for HIV and HCV infection.

349 A theoretical disadvantage of HTA is their putative adverse effects on physiological 350 processes mediated by the host factors. In this context, given that an HDV treatment will 351 occur in a context of diseased liver, assessment of safety will be a major parameter in 352 development. In this regard, it is of interest to note that pyrimidine synthesis inhibitors, such 353 as Leflunomide or Teriflunomide, are currently used for the treatment of rheumatoid arthritis 354 and multiple sclerosis[45, 46]. The safety profile of these compounds suggests that 355 pyrimidine biosynthesis is a targetable pathway for antiviral strategies. Indeed, the FDA-356 approved Leflunomide, targeting DHODH, induces uridine starvation at concentrations 357 similar to PALA concentrations we used in this study (0-100 µM)[47]. Although detailed 358 toxicity analyses in animal model and human tissues will be required to assess the

therapeutic window of PALA, the dose-response effects of Leflunomide suggests that PALA
doses required to inhibit HDV infection are most likely in a range that will have an acceptable
clinical safety profile.

In conclusion, by uncovering key host factors for HDV infection our results significantly improve the understanding of the HDV life cycle and contribute to the development of novel antiviral strategies for HDV cure.

- 365
- 366

# 367 MATERIAL AND METHODS

Human subjects. Human serum from patients with chronic HBV/HDV infection followed at the Strasbourg University Hospitals, Strasbourg, France was obtained with informed consent. PHH were obtained from liver tissue from patients undergoing liver resection for liver metastasis at the Strasbourg University Hospitals with informed consent. Protocols were approved by the local Ethics Committee of the Strasbourg University Hospitals (CPP) and the Ministry of Higher Education and Research of France (DC 2016 2616).

374

375 **Cell lines and human hepatocytes.** Huh-106[7], HepAD38[7] and HepG2-NTCP[7] cells 376 have been described. PHH were isolated and cultured as described[48].

377

378 Key Reagents. Fulvestrant (14409), DL-dihydroorotic acid (DHO, D7003), L-glutamine 379 (59202C), uridine (U3003), and tenofovir (1643601) were purchased from Sigma-Aldrich® 380 (Merck). Sparfocid acid (L-Aspartic acid, N-(phosphonoacetyl)-, disodium salt (9CI) or PALA, 381 NSC: 224131) was first obtained from the Drug Synthesis and Chemistry Branch, 382 Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National 383 Cancer Institute, National Institute of Health, Bethesda, Maryland, USA. For further analyses, 384 PALA was synthetized at the Institute of Chemistry, University of Strasbourg, as described in Supplementary Material and Methods. PreS1 peptide was synthetized by Bachem[7]. 385

HDV and HBV production and infection. The production of recombinant HDV and HBV
infectious virus as well as the protocol for HDV infection of Huh-106 cells and PHHs and for
HBV infection of HepG2-NTCP cells have been described[7, 49, 50]. A detailed protocol is
presented in Supplementary Material and Methods.

391

392 RNAi loss-of-function and small molecule screens. Screening was performed at the High 393 Throughput Screening platform of the Institut de Génétique et de Biologie Moléculaire et 394 Cellulaire (IGBMC) in Illkirch, France. The Human ON-TARGETplus "Druggable Genome" 395 siRNA Library was used for gene expression silencing. For the small molecule screen, the 396 Chemical Library® containing 1280 FDA-approved molecules was obtained from Prestwick. 397 Detailed information about both screening strategies as well as the algorithm for selection of 398 HDV-dependency candidates are presented in Supplementary Material and Methods.

399

400 Validation of CAD as a HDV host factor using individual siRNAs. Huh-106 cells were 401 reverse-transfected with the 4 individual siRNAs from the siCAD pool, a pool of siRNA 402 targeting SLC10A1 (siNTCP), or a non-targeting siRNA control (siCtrl) using Lipofectamin 403 RNAi max as described[7, 50]. Gene expression was assessed, two days after transfection, 404 by Western blot detection of CAD protein using a Rabbit monoclonal anti-CAD antibody 405 (Abcam ab40800) as previously described [7, 50].  $\beta$ -actin expression was assessed as a 406 loading control using a mouse monoclonal anti- $\beta$ -actin antibody (Sigma, A5441). Two days 407 after transfection, cells were infected by HDV and infection was assessed after 7 days as 408 described in Supplementary Material and Methods.

409

410 **Statistical analysis**. All experiments were performed at least twice in an independent 411 manner. Statistical analyses were performed using a two-tailed Mann-Whitney U test unless 412 otherwise stated; p < 0.05 (\*), p < 0.01 (\*\*), and p < 0.001 (\*\*\*) were considered statistically 413 significant. Significant *p*-values are indicated by asterisks in the individual figures and figure 414 legends. The number of biological replicates is indicated in the figure legends (n).

416 Additional methodological information are available in Online Supplementary Material.

417

418

# 419 **ACKNOWLEDGMENTS**

420 We thank J. Taylor (Fox Chase Cancer Center) for the gift of the HDV expression plasmid

421 (pSVL(D3)) and our colleagues S. Durand and M. Renaud for excellent technical support.

422

# 423 AUTHOR CONTRIBUTIONS

TFB initiated the study. TFB and ERV designed and supervised research. ERV, AW, LB and TFB set up, designed and performed the siRNA and small molecule screens. TG and PPa produced the Sparfosic acid. ERV, CB, LH, VTL and EC performed the validation experiments. CSu performed the HDV Northern blots. PPe provided human hepatocytes. ERV, AW, CB, LH, EC, MBZ, CSu, CSc, LB, TFB analyzed the data. ERV, HES and AK performed the bioinformatical analyses of the screens. ERV and TFB wrote the manuscript. All the authors approved the study.

431

# 432 COMPETING INTEREST

433 The authors have no competing interest to disclose.

434

## 435 DATA AVAILABILITY

The datasets generated in this study, including the results from both RNAi and small molecule primary screens are available within Online Supplementary Material files. The rest of the data is available from the corresponding authors upon reasonable request.

439

## 440 FUNDING

This work was supported by Inserm, the University of Strasbourg, the European Union (Infect-ERA hepBccc, ERC-2014-AdG-671231-HEPCIR and Horizon 2020 research and innovation programme under grant agreement 667273 - HEPCAR), Agence Nationale de
Recherches sur le Sida et les Hépatites Virales (ANRS 15/1099), and the French Cancer
Agency (ARC IHU201301187). This work has been published under the framework of the
LabEx ANR-10-LAB-28 and benefits from a funding from the state managed by the French
National Research Agency as part of the Investments for the Future (Investissements
d'Avenir) program. E.R.V is the recipient of an ANRS fellowship (ECTZ50121).

449

450

# 451 **REFERENCES**

1. Taylor JM. Virology of hepatitis D virus. *Semin Liver Dis* 2012;32(3):195-200.

453 2. Fattovich G, Giustina G, Christensen E, *et al.* Influence of hepatitis delta virus
454 infection on morbidity and mortality in compensated cirrhosis type B. The European
455 Concerted Action on Viral Hepatitis (Eurohep). *Gut* 2000;46(3):420-6.

456 3. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. *Lancet* 457 2011;378(9785):73-85.

458 4. Rizzetto M. Investigational drugs in development for Hepatitis D. *Expert Opin*459 *Investig Drugs* 2017;26(9):999-1005.

460 5. Sureau C, Negro F. The hepatitis delta virus: Replication and pathogenesis. J
461 *Hepatol* 2016;64(1 Suppl):S102-16.

462 6. Webb CT, Luptak A. Kinetic Parameters of trans Scission by Extended HDV463 like Ribozymes and the Prospect for the Discovery of Genomic trans-Cleaving RNAs.
464 *Biochemistry* 2018;57(9):1440-50.

Verrier ER, Colpitts CC, Bach C, et al. A targeted functional RNAi screen
uncovers Glypican 5 as an entry factor for hepatitis B and D viruses. *Hepatology*2016;63(1):35–48.

468 8. Verrier ER, Colpitts CC, Sureau C, *et al.* Hepatitis B virus receptors and 469 molecular drug targets. *Hepatol Int* 2016;10(4):567-73.

Baumert TF, Verrier ER, Nassal M, *et al.* Host-targeting agents for treatment of
hepatitis B virus infection. *Curr Opin Virol* 2015;14:41-6.

472 10. Colpitts CC, Verrier ER, Baumert TF. Targeting viral entry for treatment of
473 hepatitis B and C virus infections. *ACS Infect Dis* 2015;1(9):420–7.

474 11. Harak C, Meyrath M, Romero-Brey I, *et al.* Tuning a cellular lipid kinase
475 activity adapts hepatitis C virus to replication in cell culture. *Nat Microbiol*476 2016;2:16247.

477 12. Mailly L, Xiao F, Lupberger J, *et al.* Clearance of persistent hepatitis C virus
478 infection in humanized mice using a claudin-1-targeting monoclonal antibody. *Nat*479 *Biotechnol* 2015;33(5):549-54.

Koh C, Canini L, Dahari H, *et al.* Oral prenylation inhibition with lonafarnib in
chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebocontrolled phase 2A trial. *Lancet Infect Dis* 2015;15(10):1167-74.

483 14. Bogomolov P, Alexandrov A, Voronkova N, *et al.* Treatment of chronic
484 hepatitis D with the entry inhibitor myrcludex B: First results of a phase lb/lla study. *J*485 *Hepatol* 2016;65(3):490-8.

Li Q, Brass AL, Ng A, *et al.* A genome-wide genetic screen for host factors
required for hepatitis C virus propagation. *Proc Natl Acad Sci U S A*2009;106(38):16410-5.

489 16. Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of host proteins
490 required for HIV infection through a functional genomic screen. Science
491 2008;319(5865):921-6.

492 17. Busse-Wicher M, Wicher KB, Kusche-Gullberg M. The exostosin family:
493 proteins with many functions. *Matrix Biol* 2014;35:25-33.

494 18. Sharma N, Kumari R. Rpb4 and Rpb7: multifunctional subunits of RNA 495 polymerase II. *Crit Rev Microbiol* 2013;39(4):362-72.

496 19. Hull MW, McKune K, Woychik NA. RNA polymerase II subunit RPB9 is 497 required for accurate start site selection. *Genes Dev* 1995;9(4):481-90.

Kraus RJ, Yu X, Cordes BA, *et al.* Hypoxia-inducible factor-1alpha plays roles
in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection
through direct binding to the immediate-early BZLF1 gene promoter. *PLoS Pathog*2017;13(6):e1006404.

502 21. Morinet F, Parent M, Pillet S, *et al.* Hypoxia inducible factor one alpha and 503 human viral pathogens. *Curr Res Transl Med* 2017;65(1):7-9.

504 22. Chiu DK, Tse AP, Xu IM, *et al.* Hypoxia inducible factor HIF-1 promotes 505 myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in 506 hepatocellular carcinoma. *Nat Commun* 2017;8(1):517.

507 23. Luo D, Wang Z, Wu J*, et al.* The role of hypoxia inducible factor-1 in 508 hepatocellular carcinoma. *Biomed Res Int* 2014;2014:409272.

509 24. Lin D, Wu J. Hypoxia inducible factor in hepatocellular carcinoma: A 510 therapeutic target. *World J Gastroenterol* 2015;21(42):12171-8.

511 25. Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an
512 ancient pathway. *J Biol Chem* 2004;279(32):33035-8.

513 26. Loffler M, Fairbanks LD, Zameitat E*, et al.* Pyrimidine pathways in health and 514 disease. *Trends Mol Med* 2005;11(9):430-7.

515 27. Wang Y, Wang Z, Liu T*, et al.* Effects of flanking regions on HDV 516 cotranscriptional folding kinetics. *RNA* 2018;24(9):1229-40.

517 28. Swyryd EA, Seaver SS, Stark GR. N-(phosphonacetyl)-L-aspartate, a potent 518 transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of 519 mammalian cells in culture. *J Biol Chem* 1974;249(21):6945-50.

520 29. Lucas-Hourani M, Dauzonne D, Jorda P, *et al.* Inhibition of pyrimidine
521 biosynthesis pathway suppresses viral growth through innate immunity. *PLoS Pathog*522 2013;9(10):e1003678.

30. Reyes GR. Ribavirin: recent insights into antiviral mechanisms of action. *Curr Opin Drug Discov Devel* 2001;4(5):651-6.

525 31. Sulkowski MS, Cooper C, Hunyady B, *et al.* Management of adverse effects of 526 Peg-IFN and ribavirin therapy for hepatitis C. *Nat Rev Gastroenterol Hepatol* 527 2011;8(4):212-23.

528 32. Perry CM, Frampton JE, McCormack PL*, et al.* Nelfinavir: a review of its use in 529 the management of HIV infection. *Drugs* 2005;65(15):2209-44.

33. Jeselsohn R, Buchwalter G, De Angelis C, *et al.* ESR1 mutations-a
mechanism for acquired endocrine resistance in breast cancer. *Nat Rev Clin Oncol*2015;12(10):573-83.

533 34. Ellmen J, Hakulinen P, Partanen A*, et al.* Estrogenic effects of toremifene and 534 tamoxifen in postmenopausal breast cancer patients. *Breast Cancer Res Treat* 535 2003;82(2):103-11.

536 35. Connolly GP, Duley JA. Uridine and its nucleotides: biological actions,
537 therapeutic potentials. *Trends Pharmacol Sci* 1999;20(5):218-25.

36. Lee L, Kelly RE, Pastra-Landis SC, *et al.* Oligomeric structure of the
multifunctional protein CAD that initiates pyrimidine biosynthesis in mammalian cells. *Proc Natl Acad Sci U S A* 1985;82(20):6802-6.

541 37. Deans RM, Morgens DW, Okesli A*, et al.* Parallel shRNA and CRISPR-Cas9 542 screens enable antiviral drug target identification. *Nat Chem Biol* 2016;12(5):361-6.

543 38. Franks DM, Izumikawa T, Kitagawa H*, et al.* C. elegans pharyngeal 544 morphogenesis requires both de novo synthesis of pyrimidines and synthesis of 545 heparan sulfate proteoglycans. *Dev Biol* 2006;296(2):409-20.

546 39. Droog M, Mensink M, Zwart W. The Estrogen Receptor alpha-Cistrome 547 Beyond Breast Cancer. *Mol Endocrinol* 2016;30(10):1046-58.

40. Loustaud-Ratti V, Debette-Gratien M, Jacques J, *et al.* Ribavirin: Past, present
and future. *World J Hepatol* 2016;8(2):123-30.

550 41. Debing Y, Emerson SU, Wang Y, *et al.* Ribavirin inhibits in vitro hepatitis E 551 virus replication through depletion of cellular GTP pools and is moderately synergistic 552 with alpha interferon. *Antimicrob Agents Chemother* 2014;58(1):267-73.

553 42. Levrero M, Testoni B, Zoulim F. HBV cure: why, how, when? *Curr Opin Virol* 2016;18:135-43.

555 43. Zeisel MB, Baumert TF. Clinical development of hepatitis C virus host-556 targeting agents. *Lancet* 2017;389(10070):674-5.

van der Ree MH, de Vree JM, Stelma F, *et al.* Safety, tolerability, and antiviral
effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind,
randomised controlled trial. *Lancet* 2017;389(10070):709-17.

560 45. Zhang C, Chu M. Leflunomide: A promising drug with good antitumor potential.
561 *Biochem Biophys Res Commun* 2018;496(2):726-30.


562 46. Bar-Or A, Pachner A, Menguy-Vacheron F, *et al.* Teriflunomide and its
563 mechanism of action in multiple sclerosis. *Drugs* 2014;74(6):659-74.

564 47. Baumann P, Mandl-Weber S, Volkl A, *et al.* Dihydroorotate dehydrogenase 565 inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of 566 multiple myeloma cells. *Mol Cancer Ther* 2009;8(2):366-75.


567 48. Lupberger J, Zeisel MB, Xiao F*, et al.* EGFR and EphA2 are host factors for 568 hepatitis C virus entry and possible targets for antiviral therapy. *Nat Med* 569 2011;17(5):589-95.

- 49. Verrier ER, Yim SA, Heydmann L, *et al.* Hepatitis B Virus Evasion From Cyclic
  Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human
  Hepatocytes. *Hepatology* 2018;68(5):1695-709.
- 573 50. Verrier ER, Colpitts CC, Bach C, *et al.* Solute Carrier NTCP Regulates Innate
  574 Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes.
  575 *Cell Rep* 2016;17(5):1357–68.


- 576 FIGURE LEGENDS
- 577
- 578



580 Figure 1. Identification of host-dependency factors for HDV infection using a highthroughput RNAi screen. A. Approach with flow chart of the screen. NTCP-overexpressing 581 582 Huh7 cells (termed Huh-106) were transfected with pools of 4 siRNAs per target of the Dharmacon "Druggable genome" library 48 h before HDV infection. Infection was assessed 583 584 after 7 days by immunofluorescence. Each siRNA pool was tested in triplicate. As controls. 585 Huh-106 cells were transfected with a non-targeting siRNA control (siCtrl), siRNA targeting 586 SLC10A1 (siNTCP) and PLK1 (siPLK1, lethal for the cells) expression. Representative 587 images of HDV infection in Huh-106 cells from the primary screen are shown in B. As readout for infection, cells were stained with an anti-HDAg antibody and cell nuclei were 588 stained with DAPI. C. General effect of the siNTCP on HDV infection at the screen level. 589 590 Results are expressed as means  $\pm$  SD % HDV positive cells from siCtrl-treated cells (n = 318) and siNTCP-treated cells (n = 265). \*\*\* pvalue < 0.001 (unpaired Student's t-test). D. 591 Distribution of host-factor candidates according to their inhibitory effect on HDV infection. 592 593 The top 5% (% HDV positive cells < 8.3) were selected as candidates for further work-up. E. Selection of candidate genes from the primary screen. From the 311 genes inducing a > 45%594 595 decrease in HDV infection after silencing, candidate genes were selected depending on their robustness (p-value & FDR < 0.05), their expression in the liver (Illumina Body Map tool) and 596 597 their toxicity. Toxicity was evaluated as the percentage of viability compared to the siCtrl, 598 quantified by counting the DAPI-positive nuclei in the wells at the end of infection. From the 599 194 selected candidates, RNF130 was present twice (subset 8 and subset 10) and 2 pseudogenes (tAKR/AKR1C6P and LOC402164) were removed. 191 candidates (top 2.5%) 600 601 were further worked-up.



603 Figure 2. Pathway analysis of HDV host factors identified within the RNAi screen. The 604 identified host genes were subjected to functional enrichment pathway analysis through ToppGene Suite (https://toppgene.cchmc.org) using Kyoto Encyclopedia of Genes and 605 Genomes (KEGG) database. Pathways scoring at a FDR value of < 0.05 were considered 606 607 significant. A. Representation of the number of genes and FDR values of different KEGG pathways significantly enriched within the primary siRNA screen candidates. B. Individual 608 genes contributing to the enrichment of the significant KEGG pathways were further 609 analyzed for protein-protein interactions using STRING database. Interaction networks were 610 611 represented using Cytoscape 3.6.0.



613 Figure 3. CAD is a key host factor required for HDV infection. A. Functional validation of 614 host factors belonging to the pyrimidine biosynthesis using perturbation studies. Results are 615 presented as means ± SD % HDV infection compared to control siRNA (siCtrl, set at 100%) 616 from three independent screens (n = 9, primary screen and two validation screens performed 617 in triplicate). \*\*\* pvalue < 0.001 (unpaired Student's t-test compared to siCtrl samples). B-D. 618 CAD is required for HDV infection. Huh-106 cells were reverse-transfected with 4 individual siRNAs targeting CAD mRNA or with the pool of 4 siRNAs. Silencing efficacy was assessed 619 620 by Western blot after two days (B). One representative experiment is shown. Cells were then 621 infected with HDV and virus infection was assessed after 7 days by gRT-PCR. Results are 622 expressed as means ± SEM % HDV infection compared to siCtrl (set at 100%) from three independent experiments (n = 8) (C). Alternatively, HDV infection was assessed by 623 immunofluorescence using a patient-derived anti-HDAg antibody (D). One representative 624 625 experiment using the pool of siCAD is shown. E. HDV infection has no effect on CAD 626 expression in PHH. PHH were treated with preS1 peptide (preS1) or a peptide control (Ctrl) 627 for one hour prior to infection with HDV for seven days. Results are expressed as means ± 628 SD % HDV infection (assessed by HDV RNA levels) or CAD expression compared to control 629 peptide-treated cells (Ctrl, set at 100%) from four independent experiments (n = 8). F-G. The 630 CAD inhibitor PALA dose-dependently inhibits HDV infection in Huh-106 cells (F) and PHH 631 (G). Cells were treated with PALA at the indicated concentrations 24 h before infection with HDV. Cells were then cultured for 7 days in presence of PALA. HDV infection was assessed 632 633 by qRT-PCR. Cell viability was assessed by Presto Blue. Results are expressed as means ± SD % HDV infection or cell viability compared to untreated cells (0, set at 100%) from three 634 635 independent experiments (Huh-106,  $\mathbf{F}$ , n = 9) or as means  $\pm$  SEM % HDV infection or cell viability from three independent experiments (PHH, G, n = 8). 636





Figure 4. Characterization of CAD-HDV functional interaction. A-B-C. Uridine 638 639 complementation restores HDV infection in PALA-treated cells. Huh-106 cells were treated 640 with PALA (1 µM or 10 µM) in presence of absence of 30 µM uridine 24 h prior to infection 641 with HDV and compound treatment was maintained for 7 days. HDV infection was assessed by Northern blot (A). HDV+ corresponds to approximately 5.10<sup>7</sup> HDV RNA genome 642 643 equivalents extracted from HDV particles produced in Huh7 cells. rRNA corresponds to 644 ribosomal RNA. One representative experiment is shown. Alternatively, Huh-106 cells were 645 treated with PALA 2.5 µM in presence of absence of 30 µM uridine. HDV infection was assessed after 7 days by IF (B) or qRT-PCR (C) Results are expressed as means ± SEM % 646 647 HDV infection compared to HDV-infected untreated cells (Ctrl, set at 100%) from three independent experiments (n = 6). **D**. Absent direct interaction between HDV antigens and 648 649 CAD. Huh-106 were transfected with pSVL(D3) plasmid encoding the HDV genome. Three days after transfection, cells were lysed and HDAg-specific co-IP was performed using an 650 651 anti-HDAg antibody (Delta) or with a control antibody (Ctrl). HDV antigens and CAD expression in the original cell lysate (Input), in Flow-through control samples (FT) and in IP 652 653 eluates (IP) were assessed by Western blot. One experiment is shown. E. No IFN induction after inhibition of pyrimidine biosynthesis in Huh-106 cells. Huh-106 cells were treated with 654 655 Brequinar or PALA at the indicated concentrations. Alternatively, Huh-106 cells were 656 reverse-transfected with Poly(I:C) (100 ng). Cells were then lysed every day for three days, and IFNB1 expression was assessed by qRT-PCR. Results are expressed as means ± SD 657 relative IFNB1 expression (log10) compared to untreated or non-transfected cells (0, all set 658 659 at 1) from three independent experiments (n = 6).



662 Figure 5. PALA specifically inhibits HDV replication by targeting CAD biological function. A. Schematic representation of reactions catalyzed by CAD enzyme. Glu: 663 664 alutamine: CarbomovI-p; carbomovI phosphate: Pi; inorganic phosphate: CA; CarbamovI aspartic acid; DHO: dihydroorotate; UMP: uridine mono-phosphate. B. DHO treatment 665 restores HDV infection in PALA-treated cells. Huh-106 cells with treated with PALA 2.5 µM 666 and infected with HDV in presence or absence of L-glutamine (Glu) or DHO at the indicated 667 668 concentrations. Infection was assessed after 7 days by Northern blot detection of HDV genomic RNA. rRNA corresponds to ribosomal RNA. One experiment is shown. C. PALA 669 inhibits both HDV genomic and antigenomic production. Huh-106 cells were treated with 670 PALA 2.5 µM 24 h prior to infection with HDV. HDV genomic and antigenomic RNAs were 671 672 detected by Northern blot using specific probes 7 days after infection. HDV+ corresponds to 673 approximately 5.10<sup>7</sup> HDV RNA genome equivalents extracted from HDV particles produced in Huh7 cells. One experiment is shown. D. Kinetics of HDV infection by PALA. Huh-106 674 675 cells were pretreated with PALA at 2.5 µM and infected with HDV (conditions P#1 and P#2). 676 Cells were then cultured in presence of PALA for 48 h (P#1) or for 7 days (P#2) in presence 677 or absence of uridine (30 µM). Alternatively, Huh-106 cells were infected with HDV with no PALA pre-treatment (P#3). 16 h after viral inoculation, cells were cultured in presence of 678 PALA 2.5 µM with or without uridine (30 µM). HDV infection was assessed after 7 days by 679 680 gRT-PCR. Results are expressed as means ± SEM % HDV infection compared to HDV-681 infected untreated cells (Ctrl, set at 100%) from three independent experiments (n = 6). E. 682 PALA does not affect HDV binding. Huh-106 cells were culture for 24 h à 16°C in presence 683 of HDV particles which were pre-treated or not with heparin (30 µg/mL). HDV binding was 684 measured by gRT-PCR quantification of total HDV RNA bound to cells after 24h. Results are expressed as means ± SD % HDV binding relative to control untreated cells (Ctrl, set at 685 100%) from three independent experiments (n=9). F-H. CAD inhibition or silencing does not 686 affect HBV infection and replication. F. HBV-producing HepAD38 cells were treated with 687 688 PALA (10 µM) for three days. HBeAg and HBsAg secretion in culture supernatant was then 689 quantified by chemiluminescent immunoassay (CLIA). Cell viability was assessed by Presto

690 Blue. Results are expressed as means ± SEM % HBeAg production, HBsAg production or cell viability compared to untreated cells (0  $\mu$ M, all set at 100%) from three independent 691 experiments (n = 6). G. HepAD38 cells were treated with either tenofovir (TFV) or PALA at 692 the indicated concentrations for three days. HBV replication was assessed by quantification 693 694 of HBV DNA copies in the supernatant of treated cells by gPCR. Results are expressed as means ± SD % HBV DNA in the supernatant or cell viability compared to untreated cells (Ctrl, 695 696 all set at 100%) from three independent experiments (n = 9) H. HepG2-NTCP cells were 697 reverse-transfected with siCAD or siCtrl for two days prior to infection with HBV. HBV 698 infection was assessed after 10 days by quantification of HBeAg and HBsAg production (CLIA). Results are expressed as means ± SD % CAD expression, HBeAg production or 699 700 HBsAg production compared to siCtrl-transfected cells (siCtrl, all set at 100%) from three 701 independent experiments (n = 6).






Figure 6. ESR1 inhibitor Fulvestrant inhibits HDV replication by suppression of CAD 704 705 expression. A. Small molecule screen flow chart. Huh-106 cells were treated with individual 706 compounds belonging to the Prestwick Chemical library (10 µM) one day prior to infection with HDV. Infection was assessed after 7 days by immunofluorescence. Every compound 707 708 was tested in triplicate. **B**. ESR1 modulators affect HDV infection. From the primary screen, 709 Fulvestrant (an ESR1 inhibitor) from the one hand, Tamoxifen and Toremifen from the other 710 hand (two agonists/modulators of ESR1) exhibited antiviral or proviral activity against HDV, 711 respectively. Results are presented as means ± SD % HDV infected cells (n = 3). C. 712 Fulvestrant dose-dependently inhibits HDV infection. Huh-106 cells were treated with 713 Fulvestrant at the indicated concentrations and then infected with HDV for seven days. Results are expressed as means ± SD % HDV infected cells from three independent 714 715 experiments (n = 9). **D.** Short Fulvestrant treatment for 48 h following virus inoculation 716 inhibits HDV infection. Huh-106 cells were infected with HDV and then treated with 717 Fulvestrant (10 µM) or DMSO for 48 h. Cells were then culture in absence of drug and infection was assessed after 7 days by IF. One representative experiment is shown. E. 718 719 Fulvestrant antiviral activity is associated with slight cytotoxicity. Cell viability was assessed after 48 h and after 7 days by Presto blue. HDV infection was assessed after 7 days by qRT-720 PCR. Results are expressed as means ± SD % HDV infection (HDV RNA) or cell viability 721 compared to untreated HDV-infected cells (Ctrl, set at 100%) from three independent 722 723 experiments (n = 9). F. Fulvestrant antiviral activity in PHH. PHH were infected with HDV and 724 then treated with Fulvestrant for 48 h at the indicated concentrations. Results are expressed 725 as means ± SD % HDV infection (HDV RNA) or cell viability compared to untreated HDVinfected PHH (Ctrl, set at 100%) from two independent experiments (n = 6). G. Fulvestrant 726 727 inhibits CAD expression. Huh-106 cells and PHH were treated with Fulvestrant (Fulv, 10 µM) 728 or DMSO for 72h. CAD expression was assessed by Western blot.